Trials / Completed
CompletedNCT04652349
Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia
A Randomized, Double-Blinded, Multi-center, Phase 3 Study to Evaluate Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 279 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the safety and clinical efficacy of HGP1910 and HCP1903 in patients with primary hypercholesterolemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HGP1910 | Take it once daily for 8 weeks orally. |
| DRUG | HCP1903 | Take it once daily for 8 weeks orally. |
| DRUG | HGP1909 | Take it once daily for 8 weeks orally. |
| DRUG | HGP1911 | Take it once daily for 8 weeks orally. |
Timeline
- Start date
- 2020-07-06
- Primary completion
- 2020-12-17
- Completion
- 2021-01-14
- First posted
- 2020-12-03
- Last updated
- 2021-03-05
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04652349. Inclusion in this directory is not an endorsement.